The Swiss Market Index (SMI) is navigating seasonal volatility in September, following a strong second-quarter rally that reached new all-time highs. While a minor correction is expected, concerns persist over potential rate hikes by the Federal Reserve, European Central Bank (ECB), and Bank of Japan (BoJ), which could dampen market sentiment. Lombard Odier’s Nannette Hechler-Fayd’herbe notes that while fundamentals remain supportive, the outlook hinges on global economic resilience and the ability of Swiss firms to sustain profitability amid higher interest rates and geopolitical tensions.
The Swiss equity market’s adaptability is a key strength, with companies maintaining earnings growth despite elevated borrowing costs. Hechler-Fayd’herbe anticipates the SMI could reach 15,000 points by 2027, reflecting broader market optimism. However, sectoral disparities persist: while pharmaceuticals face patent expirations, innovation in drug development offers offsetting opportunities. Consumer staples and defensive sectors remain resilient, but weaker performers—such as lagging giants like Roche and Nestlé—could drag the index lower unless they improve.
Beyond the SMI, Lombard Odier favors small- and mid-cap indices (SMIM) for their cyclical recovery potential, particularly as geopolitical uncertainties in 2025 ease. Emerging markets also present attractive valuations, though the firm has shifted from neutrality to overweight exposure since early 2026, after initially prioritizing developed-market sectors. Japan remains a standout, while Chinese volatility remains a cautionary note.
Dividend-paying stocks remain a cornerstone of Lombard Odier’s strategy, as research underscores their role as a stable wealth accumulation tool when reinvested. While individual equity risk persists, dividends offer lower volatility compared to growth-focused investments. The Swiss franc’s low yields further justify a higher equity allocation for domestic investors, though alternatives like real estate, private equity, or hedge funds may also play a role.
The firm’s neutral SMI positioning reflects its belief that global equities will outperform over the next 12 months, driven by robust corporate earnings and a broadening economic recovery fueled by artificial intelligence and industrial revival. However, the sector-specific risks—particularly in pharmaceuticals—highlight the need for active stock selection.
In summary, while the Swiss market shows signs of stabilization, investors should remain selective, prioritizing dividend stability and sectoral resilience amid evolving macroeconomic conditions.
